3.Discussion and Prospect
Lung illnesses frequently do not occur in isolation; instead, they may
develop in combination with other systemic diseases, or numerous lung
diseases may occur simultaneously, or due to a causative factor causes
the disease to appear in diverse processes with varying clinical
symptoms and disease types. Microorganisms, for example, might cause
pneumonia at an early stage, but severe pneumonia may cause ARDS or even
a systemic inflammatory response syndrome, which could lead to pulmonary
fibrosis in a long term, pulmonary fibrosis increases the risk of lung
cancer by 7% to 20%[121]. This review addresses the results and
developments of lncRNA-miRNA interactions in the development,
prevention, and therapy of various common and thoroughly researched lung
diseases. Some star lncRNA molecules have been extensively studied in a
variety of diseases. MALAT1 and NEAT1, which are involved in acute and
chronic inflammation of numerous causes of lung, as well as MALAT1 and
HOTAIR, which are expressed in several tumors including lung cancer.
We further noticed that research into the mechanism of lncRNA-miRNA
interactions in lung diseases is more focused on the ceRNA mechanism, in
which lncRNA sponges binding miRNAs, suppresses miRNA binding, and
silences downstream mRNA translation. Finding potential biomarkers for
disease diagnosis, degree, prognosis, or targets for therapy required an
understanding of the mechanism of lung disease formation and the role
played by ncRNAs in the mechanism of cure. All of that is accomplished
by constructing the lncRNA-miRNA action network. However, the
involvement of lncRNA-miRNA interactions in lung diseases is a
sophisticated network of inter-crosstalk among innumerable ncRNAs, the
roles and processes of which are yet unclear.